Telix Pharmaceuticals Ltd's (ASX:TLX) Christian Behrenbruch speaks with Proactive's Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020. They're a Melbourne-headquartered global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly targeted radiation.
Telix Pharmaceuticals with Proactive at the ASX Small and Mid-Cap Conference 2020
Quick facts: Telix Pharmaceuticals Ltd
Price: 1.75 AUD
Market Cap: $444.4 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE